Citi raised the firm’s price target on Oric Pharmaceuticals (ORIC) to $16 from $12 and keeps a Buy rating on the shares following the Q3 report. The firm views the early data for ORIC-944 as promising.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ORIC:
- Oric Pharmaceuticals’ 2025 Restructuring: Potential Risks and Financial Implications
- Promising Potential of ORIC-944 in mCRPC Treatment Boosts Buy Rating and Price Target
- Oric Pharmaceuticals price target raised to $23 from $19 at H.C. Wainwright
- Promising Developments and Strong Cash Position Justify Buy Rating for ORIC Pharmaceuticals
- Oric Pharmaceuticals price target raised to $15 from $12 at Oppenheimer